Welcome to our dedicated page for Faeth Therapeutics SEC filings (Ticker: FTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Faeth Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Faeth Therapeutics's regulatory disclosures and financial reporting.
Faeth Therapeutics, Inc. filed an initial ownership report for its Chief Financial Officer, Brian C. Stephenson, showing a stock option to purchase common stock. The option covers 166,435 underlying shares at an exercise price of $29.37 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the shares subject to the option vest and become exercisable on March 11, 2027. The remaining shares vest in 36 equal monthly installments thereafter, so the option is fully vested by March 11, 2030, subject to his continuous service with the company.
Faeth Therapeutics, Inc. shareholders Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen reported beneficial ownership stakes in the company via a joint Schedule 13G filing. The filing lists 2,020,103 shares (7.8%) for Suvretta and Mr. Cowen and 1,722,652 shares (6.7%) for Averill, based on 25,778,754 shares outstanding as of June 15, 2026. The filing states these securities are directly owned by advisory clients of Suvretta Capital, that Mr. Cowen is the control person and managing member of Suvretta, and that a joint filing agreement and control-person identification exhibit are attached.
Faeth Therapeutics: S2G Investments, LLC reports beneficial ownership of 2,575,401 shares of common stock, equal to 9.99% of the class as of June 15, 2026. The filing states these shares reflect conversion on June 15, 2026 of Series B Non‑Voting Convertible Preferred Stock, each convertible into 1,000 common shares, and that 25,778,754 shares outstanding is the denominator used for the percentage. The filer also holds 344.271 shares of Series B Preferred (approximately 344,271 common shares on an as‑converted basis) that are not deemed beneficially owned due to a Beneficial Ownership Limitation the reporting person elected at 9.99%.